<DOC>
	<DOCNO>NCT01722890</DOCNO>
	<brief_summary>Primary Objective : The primary aim study : 1.To identify validate panel molecular cytogenetic biomarkers able predict Durable Complete Response ( DCR ) chemotherapy trastuzumab patient HER2-positive locally advanced metastatic breast cancer . Secondary Objective : The secondary aim study : 1 . To perform comprehensive exploration molecular cytogenetic characteristic DCR patient identify possible correlation tumour 's biological cytogenetic characteristic degree clinical response trastuzumab ; 2 . To produce data preparation translational study HER2-positive breast cancer .</brief_summary>
	<brief_title>CharactHer . ICORG 12-09 , V3</brief_title>
	<detailed_description>Type Study : Translational This pilot retrospective laboratory-based cohort study . Eligible patient identify one participate institution systematic cross-matching datasets Medical Oncology , Pathology Pharmacy Departments . Patient Population : Cohort 1 : TNM stage II-IV breast cancer patient highly trastuzumab-sensitive tumour . Cohort 2 : ( Control group ) TNM stage II-IV breast cancer patient trastuzumab-refractory disease .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Inclusion criterion Cohort 1 : 1 . Histologically proven AJCC TNM stage IIIV invasive breast cancer 2 . HER2positivity define score 3+ IHC and/or HER2/neu amplification FISH test ( HER2/CEP17 ratio &gt; 2.0 PathVysion test ) 3 . Evidence complete response ( CR ) accord RECIST 1.1 criterion last least 36 month ( stage IV patient ) follow firstline chemotherapy trastuzumab 4 . Pathological Complete Response ( pCR ) follow neoadjuvant chemotherapy ( CT ) trastuzumab ( stage IIIII patient ) . pCR define evidence residual invasive carcinoma breast ( ductal carcinoma situ ( DCIS ) allow ) AND examine lymph node ( micrometastases isolate tumour cell allow ) . 5 . At least one FFPE archive tissue sample primary tumour and/or metastatic site ( ) available laboratory analyse 6 . Adequate follow information Inclusion criterion Cohort 2 : 1 . Histologically proven AJCC TNM stage IIIV invasive breast cancer 2 . HER2positivity define score 3+ IHC and/or HER2/neu amplification FISH test ( HER2/CEP17 ratio &gt; 2.0 PathVysion test ) 3 . Progression disease accord RECIST 1.1 receive trastuzumab ( association chemotherapy single agent maintenance therapy ) within 6 month last dose trastuzumab ( stage IV patient ) 4 . Residual invasive tumour breast large 2cm /or least one micro macrometastasis axillary lymph node follow preoperative trastuzumabcontaining chemotherapy ( stage IIIII patient ) 5 . At least one FFPE archive tissue sample primary tumour and/or metastatic site ( ) available laboratory analyse 6 . Adequate follow information 1 . Any deviation mention Inclusion criterion</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HER2-positive breast cancer</keyword>
	<keyword>durable complete response</keyword>
	<keyword>cytogenetic characteristic</keyword>
	<keyword>molecular characteristic</keyword>
	<keyword>trastuzumab</keyword>
</DOC>